Literature DB >> 26638912

A bivalent role of TIP60 histone acetyl transferase in human cancer.

Gaëlle Judes1,2, Khaldoun Rifaï1,2, Marjolaine Ngollo1,2, Marine Daures1,2, Yves-Jean Bignon1,2, Frédérique Penault-Llorca2,3, Dominique Bernard-Gallon1,2.   

Abstract

Acetylation is a major modification that is required for gene regulation, genome maintenance and metabolism. A dysfunctional acetylation plays an important role in several diseases, including cancer. A group of enzymes-lysine acetyltransferases are responsible for this modification and act in regulation of transcription as cofactors and by acetylation of histones and other proteins. Tip60, a member of MYST family, is expressed ubiquitously and is the acetyltransferase catalytic subunit of human NuA4 complex. This HAT has a well-characterized involvement in many processes, such as cellular signaling, DNA damage repair, transcriptional and cellular cycle. Aberrant lysine acetyltransferase functions promote or suppress tumorigenesis in different cancers such as colon, breast and prostate tumors. Therefore, Tip60 might be a potential and important therapeutic target in the cancer treatment; new histone acetyl transferase inhibitors were identified and are more selective inhibitors of Tip60.

Entities:  

Keywords:  HAT inhibitor; Tip60; acetyltransferase; cancer; oncogene; suppressor of tumor

Mesh:

Substances:

Year:  2015        PMID: 26638912     DOI: 10.2217/epi.15.76

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  24 in total

1.  Recurrent chromosomal translocations in sarcomas create a megacomplex that mislocalizes NuA4/TIP60 to Polycomb target loci.

Authors:  Nikita Avvakumov; Marie-Eve Lalonde; Nader Alerasool; Charles Joly-Beauparlant; Karine Jacquet; Amel Mameri; Deepthi Sudarshan; Jean-Philippe Lambert; Justine Rousseau; Catherine Lachance; Eric Paquet; Lara Herrmann; Samarth Thonta Setty; Jeremy Loehr; Marcus Q Bernardini; Marjan Rouzbahman; Anne-Claude Gingras; Benoit Coulombe; Arnaud Droit; Mikko Taipale; Yannick Doyon; Jacques Côté
Journal:  Genes Dev       Date:  2022-06-16       Impact factor: 12.890

Review 2.  The Role of E3 Ligase Pirh2 in Disease.

Authors:  Alexandra Daks; Olga Fedorova; Sergey Parfenyev; Ivan Nevzorov; Oleg Shuvalov; Nickolai A Barlev
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

3.  Chromatin regulators and their impact on DNA repair and G2 checkpoint recovery.

Authors:  Veronique A J Smits; Ignacio Alonso-de Vega; Daniël O Warmerdam
Journal:  Cell Cycle       Date:  2020-07-30       Impact factor: 4.534

4.  TIP60/P400/H4K12ac Plays a Role as a Heterochromatin Back-up Skeleton in Breast Cancer.

Authors:  Mouhamed Idrissou; Tiphanie Boisnier; Anna Sanchez; Fatma Zohra Houfaf Khoufaf; Frederique Penault-Llorca; Yves-Jean Bignon; Dominique Bernard-Gallon
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

5.  Roles for the Histone Modifying and Exchange Complex NuA4 in Cell Cycle Progression in Drosophila melanogaster.

Authors:  Kerry Flegel; Olga Grushko; Kelsey Bolin; Ellen Griggs; Laura Buttitta
Journal:  Genetics       Date:  2016-05-16       Impact factor: 4.562

6.  Epigenetic plasticity of enhancers in cancer.

Authors:  Jie Yao; Ji Chen; Lian-Yun Li; Min Wu
Journal:  Transcription       Date:  2020-01-16

Review 7.  Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex.

Authors:  Omeima Abdullah; Ziad Omran; Salman Hosawi; Ali Hamiche; Christian Bronner; Mahmoud Alhosin
Journal:  Genes (Basel)       Date:  2021-04-22       Impact factor: 4.096

Review 8.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

9.  Schizosaccharomyces pombe KAT5 contributes to resection and repair of a DNA double-strand break.

Authors:  Tingting Li; Ruben C Petreaca; Susan L Forsburg
Journal:  Genetics       Date:  2021-05-17       Impact factor: 4.562

Review 10.  Targeting cancer using KAT inhibitors to mimic lethal knockouts.

Authors:  James A L Brown; Emer Bourke; Leif A Eriksson; Michael J Kerin
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.